Wyeth Can't Kick Class Cert. In Canadian Suit Over Premarin

Law360, New York (June 15, 2012, 7:43 PM EDT) -- A Canadian appeals panel on Friday upheld the certification of a class of consumers who claim Wyeth Canada Inc.'s hormone drug Premarin causes breast cancer, clearing the way for the case to proceed to trial.

Wyeth Canada, part of Pfizer Inc., had sought to have the certification overturned, arguing that the lower-court judge who ordered it had ignored evidence disproving a link between Premarin and cancer, set an unmanageable class period and allowed a claim based on the Business Practices and Consumer Protection Act that was...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.